<DOC>
	<DOCNO>NCT00872352</DOCNO>
	<brief_summary>In present study planning study electrophysiological change relate dose time bortezomib administration newly diagnose patient MM , first month treatment 6 month end . In addition possible correlation incidence BIPN subtype myeloma risk factor investigate .</brief_summary>
	<brief_title>Evaluation Bortezomib Induced Peripheral Neuropathy Multiple Myeloma ( MM ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Age &gt; 18 Patients Multiple Myeloma stage II , III ( Durie Salmon stag ) prior Bortezomib Therapy Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 Be willing able comply protocol treatment duration study Patient 's write informed consent Multiple Myeloma progression Incidence Relapsed Refractory Myeloma Patients exist neuropathy time diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Peripheral Neuropathy</keyword>
	<keyword>evaluation</keyword>
	<keyword>evaluation electrophysiological change relate dose time bortezomib administration</keyword>
	<keyword>investigation correlation incidence BIPN subtype myeloma</keyword>
</DOC>